Agree Sillazze
I am sensing (and it is nothing more than a sense from observation) that the issues with Daybue side affects will plateau and even improve. Meaning that I expect a slight reversal of the drop out rate. After 12 months of data and analysis the Acadia team I believe are far more prepared to help new patients adjust.
Also as time progresses I expect compliance rates to increase as families who are very gradually increasing dosages start approaching their target dosage.
Will be an interesting couple of quarters as we approach entry into the Canadian market.
Agree SillazzeI am sensing (and it is nothing more than a sense...
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$19.61 |
Change
0.300(1.55%) |
Mkt cap ! $2.536B | |||
| Open | High | Low | Value | Volume |
| $19.39 | $19.98 | $19.38 | $3.489M | 176.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 70 | $19.59 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $19.62 | 5 | 1 |
View Market Depth
| Last trade - 11.25am 14/06/2024 (20 minute delay) ? |
|
|||||
|
Last
$19.55 |
Change
0.300 ( 0.83 %) |
||||
| Open | High | Low | Volume | ||
| $19.41 | $19.97 | $19.39 | 25703 | ||
| Last updated 11.44am 14/06/2024 ? | |||||
| NEU (ASX) Chart |